BR112022024063A2 - Polipeptídeos de coronavírus 2 da síndrome respiratória aguda grave (sars-cov-2) e usos dos mesmos para fins de vacina - Google Patents

Polipeptídeos de coronavírus 2 da síndrome respiratória aguda grave (sars-cov-2) e usos dos mesmos para fins de vacina

Info

Publication number
BR112022024063A2
BR112022024063A2 BR112022024063A BR112022024063A BR112022024063A2 BR 112022024063 A2 BR112022024063 A2 BR 112022024063A2 BR 112022024063 A BR112022024063 A BR 112022024063A BR 112022024063 A BR112022024063 A BR 112022024063A BR 112022024063 A2 BR112022024063 A2 BR 112022024063A2
Authority
BR
Brazil
Prior art keywords
cov
sars
polypeptides
coronavirus
epitopes
Prior art date
Application number
BR112022024063A
Other languages
English (en)
Inventor
Levy Yves
Zurawski Gérard
Zurawski Sandra
Lacabaratz Christine
Cardinaud Sylvain
Surenaud Mathieu
Original Assignee
Inst Nat Sante Rech Med
Baylor Res Institute
Assist Publique Hopitaux Paris Aphp
Univ Paris Val De Marne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Baylor Res Institute, Assist Publique Hopitaux Paris Aphp, Univ Paris Val De Marne filed Critical Inst Nat Sante Rech Med
Publication of BR112022024063A2 publication Critical patent/BR112022024063A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

POLIPEPTÍDEOS DE CORONAVÍRUS 2 DA SÍNDROME RESPIRATÓRIA AGUDA GRAVE (SARS-COV-2) E USOS DOS MESMOS PARA FINS DE VACINA. A pandemia de coronavírus 2 da Síndrome Respiratória Aguda Grave (SARS-CoV-2) inegavelmente emergiu como a maior ameaça global à saúde da humanidade neste século. As vacinas de SARS-CoV-2 serão essenciais para reduzir a morbidade e a mortalidade se o vírus se estabelecer na população. Os inventores criaram vacinas candidatas contra SARS-CoV-2. Em particular, os inventores identificaram epítopos específicos a serem incluídos em vacinas candidatas graças a análise in silico da sequência de aminoácidos dessas proteínas para mapear epítopos MHC-I e -II previstos por software online (NetMHC-4.0 e NetMHCII-2.3) e software de previsão de ligação de peptídeos. Epítopos de células B também foram mapeados usando software online (BepiPred-2.0 e Discotope), assim como regiões ricas em epítopos cujas sequências são homólogas entre SARS-CoV-2 e -CoV-1. Finalmente, os inventores geraram alguns anticorpos CD40 específicos compreendendo um ou mais polipeptídeos SARS-CoV-2 da presente invenção e que são adequados para fins de vacina. Portanto, a presente invenção refere-se a polipeptídeos SARS-CoV-2 e seus usos para fins de vacina.
BR112022024063A 2020-05-26 2021-05-26 Polipeptídeos de coronavírus 2 da síndrome respiratória aguda grave (sars-cov-2) e usos dos mesmos para fins de vacina BR112022024063A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20305550 2020-05-26
EP20306415 2020-11-20
EP21305092 2021-01-26
EP21305482 2021-04-12
PCT/EP2021/064098 WO2021239838A2 (en) 2020-05-26 2021-05-26 Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes

Publications (1)

Publication Number Publication Date
BR112022024063A2 true BR112022024063A2 (pt) 2023-01-31

Family

ID=76159441

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024063A BR112022024063A2 (pt) 2020-05-26 2021-05-26 Polipeptídeos de coronavírus 2 da síndrome respiratória aguda grave (sars-cov-2) e usos dos mesmos para fins de vacina

Country Status (9)

Country Link
US (1) US20230212231A1 (pt)
EP (1) EP4157343A2 (pt)
JP (1) JP2023528017A (pt)
KR (1) KR20230042222A (pt)
BR (1) BR112022024063A2 (pt)
CA (1) CA3184802A1 (pt)
CO (1) CO2022018389A2 (pt)
MX (1) MX2022014943A (pt)
WO (1) WO2021239838A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022043551A2 (en) * 2020-08-31 2022-03-03 Curevac Ag Multivalent nucleic acid based coronavirus vaccines
WO2023088968A1 (en) * 2021-11-17 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Universal sarbecovirus vaccines
CN114807179B (zh) * 2022-06-01 2022-10-21 广州达博生物制品有限公司 一种新型冠状病毒肺炎疫苗的构建与应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
DE68921982T4 (de) 1988-06-14 1996-04-25 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
CN101940189A (zh) 2000-11-30 2011-01-12 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7488802B2 (en) 2002-12-23 2009-02-10 Wyeth Antibodies against PD-1
CN100588430C (zh) * 2004-02-20 2010-02-10 复旦大学 基于表位的SARS-Cov基因疫苗及其构建
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
EP1907424B1 (en) 2005-07-01 2015-07-29 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
BRPI0807344A2 (pt) 2007-02-02 2014-05-20 Baylor Res Inst Antígenos multivariáveis complexados com anticorpo monoclonal humanizado de direcionamento
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010104747A2 (en) 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted vaccines
ES2890230T3 (es) 2008-07-16 2022-01-18 Baylor Res Institute Vacuna contra el VIH basada en el direccionamiento de Gag y Nef maximizado a células dendríticas
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
US20110223188A1 (en) 2008-08-25 2011-09-15 Solomon Langermann Targeted costimulatory polypeptides and methods of use to treat cancer
PL2376535T3 (pl) 2008-12-09 2017-09-29 F.Hoffmann-La Roche Ag Przeciwciała ANTY-PD-L1 i ich zastosowanie do nasilania działania limfocytów T
US8289808B2 (en) 2009-04-16 2012-10-16 Chevron U.S.A., Inc. System and method to estimate compressional to shear velocity (VP/VS) ratio in a region remote from a borehole
AU2010291939B2 (en) 2009-09-14 2012-11-15 Baylor Research Institute Vaccines directed to Langerhans cells
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
SI3279215T1 (sl) 2009-11-24 2020-07-31 Medimmune Limited Usmerjena vezavna sredstva proti B7-H1
WO2012021834A1 (en) 2010-08-13 2012-02-16 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
WO2012059882A2 (en) 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
DK2785375T3 (da) 2011-11-28 2020-10-12 Merck Patent Gmbh Anti-pd-l1-antistoffer og anvendelser deraf
WO2014085580A1 (en) * 2012-11-28 2014-06-05 Baylor Research Institute Methods and compositions involving a flu vaccine
JP2016532711A (ja) 2013-09-06 2016-10-20 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 免疫調節剤としての１，３，４−オキサジアゾール及び１，３，４−チアジアゾールの誘導体
PL3363790T3 (pl) 2013-09-06 2020-07-27 Aurigene Discovery Technologies Limited Pochodne 1,2,4-oksadiazolu jako immunomodulatory
US10849972B2 (en) * 2018-11-27 2020-12-01 King Adulaziz University Trimeric S1-CD40L fusion protein vaccine against Middle East respiratory syndrome-coronavirus

Also Published As

Publication number Publication date
WO2021239838A2 (en) 2021-12-02
EP4157343A2 (en) 2023-04-05
CA3184802A1 (en) 2021-12-02
CO2022018389A2 (es) 2023-02-06
US20230212231A1 (en) 2023-07-06
KR20230042222A (ko) 2023-03-28
MX2022014943A (es) 2023-03-08
JP2023528017A (ja) 2023-07-03
WO2021239838A3 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
BR112022024063A2 (pt) Polipeptídeos de coronavírus 2 da síndrome respiratória aguda grave (sars-cov-2) e usos dos mesmos para fins de vacina
EA202192570A1 (ru) Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
BR112019018307A2 (pt) Plataforma para identificação de peptídeos imunogênicos baseada em população
EA202091710A1 (ru) Антитела против cd73 и способы их применения
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
Job et al. Broadened immunity against influenza by vaccination with computationally designed influenza virus N1 neuraminidase constructs
CL2021000517A1 (es) Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
Del Campo et al. OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
BR112013032723A2 (pt) antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
BR112018071686A2 (pt) exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus
PE20171336A1 (es) Anticuerpos contra tau y sus usos
BR112021026439A2 (pt) Vacina para febre suína africana
BR112014018884A2 (pt) antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b
EA202090049A1 (ru) Поксвирусные векторы, кодирующие антигены вич, и способы их применения
EA201892735A1 (ru) Состав вакцины против hiv
BR112016016737A2 (pt) Peptídeos, dispositivos e métodos para detecção de anticorpos contra anaplasma
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
BR112022011099A2 (pt) Tratamento de doenças relacionadas ao vírus da hepatite b
RU2015106916A (ru) Полипептиды clostridium difficile в виде вакцины
BR112022026580A2 (pt) Composições e métodos para induzir uma resposta imune contra coronavírus
Aparicio et al. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses
AR051853A1 (es) Vacuna para aumentar el crecimiento basada en epitopes neutralizantes